Frederick J Meyers
Affiliation: University of California
- Perspectives on palliative care: a chair of medicine viewpointF J Meyers
University of California, Davis, Department of Internal Medicine, Sacramento, California 95817, USA
J Palliat Med 2:371-5. 1999..Research and new models of palliative care can be developed, often in conjunction with the community. The provision of longitudinal care and symptom management are not incongruous with the mission of research. They are inseparable...
- Strengthening the career development of clinical translational scientist trainees: a consensus statement of the Clinical Translational Science Award (CTSA) Research Education and Career Development CommitteesFrederick J Meyers
University of California, Davis, School of Medicine, Sacramento, California, USA
Clin Transl Sci 5:132-7. 2012..Implied themes include an effective and diverse job force and the requirement for a well-crafted public policy that supports continued investments in science education...
- Creating the future biomedical research workforceFrederick J Meyers
University of California, Davis, School of Medicine, Sacramento, CA 95817, USA
Sci Transl Med 3:102fs5. 2011..As an NIH task force ponders the future of the U.S. biomedical research workforce, clinical and translational scientists can contribute crucial insights and should share comments by 7 October 2011...
- Redesigning residency training in internal medicine: the consensus report of the Alliance for Academic Internal Medicine Education Redesign Task ForceFrederick J Meyers
Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA 95817, USA
Acad Med 82:1211-9. 2007....
- Palliative care for prison inmates: "don't let me die in prison"John F Linder
Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Cancer Center, University of California, Davis, Sacramento, Calif
JAMA 298:894-901. 2007..We also include practical recommendations to community-based physicians working with incarcerated or recently released prisoners and describe solutions that can be implemented on an individual and systems basis...
- A strategy for the simultaneous provision of pre-operative palliative care for patients awaiting liver transplantationLorenzo Rossaro
Division of Gastroenterology and Hepatology, University of California, Davis Medical Center, 2233 Stockton Boulevard, HSF 2nd Floor, Sacramento, CA 95817, USA
Transpl Int 17:473-5. 2004
- Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative careFrederick J Meyers
Department of Internal Medicine, Cancer Center, The University of California Davis Health System, Sacramento, California 95817, USA
J Pain Symptom Manage 28:548-56. 2004..SC may enhance coordination of care and facilitate patients' explicit transition from curative intent to palliative intent. In order to validate this approach, a randomized comparative trial evaluating SC has been initiated...
- An approach to develop effective health care decision making for women in prisonSheila R Enders
Department of Internal Medicine, Division of Hematology Oncology, University of California, Davis Medical Center, Sacramento, CA 95817, USA
J Palliat Med 8:432-9. 2005..Maintaining a balance between the Eighth Amendment rights of prisoners and their status as wards of the state is a concern for inmates and for those responsible for their care...
- The Palliative Care in Assisted Living (PCAL) pilot study: successes, shortfalls, and methodological implicationsAnthony F Jerant
Department of Family and Community Medicine, University of California Davis School of Medicine, 4860 Y Street, Suite 2300, Sacramento, CA 95817, USA
Soc Sci Med 62:199-207. 2006..Further studies exploring the TLC model appear warranted...
- Can patient coaching reduce racial/ethnic disparities in cancer pain control? Secondary analysis of a randomized controlled trialDonna Kalauokalani
Department of Anesthesiology and Pain Medicine, Division of Pain Medicine, University of California, Davis, California, USA
Pain Med 8:17-24. 2007..Therefore, we examined whether patient coaching could reduce disparities in pain control in a secondary analysis of a randomized controlled trial...
- Racial and ethnic differences in treatment and survival among adults with primary extremity soft-tissue sarcomaSteve R Martinez
Division of Surgical Oncology, University of California at Davis Cancer Center, Sacramento, CA 95817, USA
Cancer 112:1162-8. 2008..The authors assessed racial/ethnic differences in patient- and tumor-specific characteristics, treatment, and disease-specific survival in a population of adults with ESTS...
- The utility of the model for end-stage liver disease score: a reliable guide for liver transplant candidacy and, for select patients, simultaneous hospice referralValentina Medici
Department of Internal Medicine, University of California, Davis, Sacramento, CA 95817, USA
Liver Transpl 14:1100-6. 2008..A higher MELD score might augment physician judgment as to hospice referral. Hospice care for selected patients may be an effective strategy to improve the care of end-stage liver disease patients waiting for LT...
- Radical palliative surgery: new limits to pursueMindy Young-Spint
University of California Davis School of Medicine, 2315 Stockton Blvd, Sacramento, CA 95817, USA
Pediatr Surg Int 25:917-21. 2009..We believe that the option of surgical palliation in this case was warranted and should be an option for similar cases in the future...
- Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II TrialPrimo N Lara
Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
Cancer 100:2125-31. 2004..The authors screened for HER-2 overexpression in patients developing hormone-refractory prostate carcinoma (HRPC) and conducted a Phase II trial of trastuzumab plus docetaxel in HER-2-positive patients...
- The TLC model of palliative care in the elderly: preliminary application in the assisted living settingAnthony F Jerant
Department of Family and Community Medicine, University of California Davis School of Medicine, Sacramento, Calif 95817, USA
Ann Fam Med 2:54-60. 2004..Preliminary results of an intervention for elderly assisted living residents based on the TLC model support its promise as a framework for optimizing palliative care of elders...
- Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6ROBERT T O'DONNELL
Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California Davis Medical Center, Sacramento, California 95816, USA
Prostate 50:27-37. 2002..55 MBq;150 microCi) has resulted in durable responses. To make radioimmunotherapy (RIT) more effective, the radiation-enhancing drugs Taxol (paclitaxel) and Taxotere (docetaxel) were tested for synergy with 90Y-DOTA-peptide-ChL6...
- Hospice care for the incarcerated in the United States: an introductionJohn F Linder
University of California, Davis, Health System, Sacramento, California 95817, USA
J Palliat Med 5:549-52. 2002..Implementing hospice behind bars has some unique challenges in addition to those inherent in hospice work. This series will provide an in-depth look at four hospice programs for inmates in the United States...
- Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?Regina Gandour-Edwards
Department of Pathology, School of Medicine, University of California Davis, 95817, USA
Cancer 95:1009-15. 2002..Thus, the authors evaluated a possible correlation between HER2 expression in patients with high-grade, muscle-invasive urothelial carcinoma of the bladder and outcome in patients who received paclitaxel-based chemotherapy...
- Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara
Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
Cancer 100:82-8. 2004..However, the toxicities of platinum-based chemotherapy are considerable. Regimens with reduced toxicity that are applicable to a broader group of TCC patients without sacrificing activity therefore are of interest...
- HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening TrialPrimo N Lara
University of California Davis Cancer Center, Division of Hematology Oncology, 4501 X Street, Sacramento, CA 95817, USA
Cancer 94:2584-9. 2002..The authors report the results of HER-2 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER-2-overexpressing prostate carcinoma...
- Medical and surgical palliative care of patients with urological malignanciesJoon Ha Ok
Department of Urology, University of California Davis, Sacramento, California 95817, USA
J Urol 174:1177-82. 2005..We reviewed the various palliative treatments available for the 3 most common urological malignancies, namely prostate cancer, bladder cancer and renal cancer...
- An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in CaliforniaCynthia L Martel
University of California Davis Cancer Center, Sacramento, California 95817, USA
Cancer J 10:294-300. 2004..In 2002, a new California law (SB37) required insurers to reimburse routine costs of care for cancer trials...
- Prison hospice and pastoral care services in CaliforniaJohn F Linder
Department of Internal Medicine and the West Coast Center for Palliative Education, University of California, Davis, Sacramento 95817, USA
J Palliat Med 5:903-8. 2002..Family and friends of the deceased in the free community are followed by phone, mail, and primarily through referral to resources in their local area...
- SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibitionPrimo N Lara
University of California Davis Cancer Center, Sacramento, California 95817, USA
Clin Cancer Res 9:4772-81. 2003..Efficacy was correlated with serial plasma VEGF and plasminogen activator inhibitor-1 levels and with positron emission tomography scans...
- Current strategies in the management of hormone refractory prostate cancerCynthia L Martel
Division of Hematology and Oncology, University of California, Davis, Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
Cancer Treat Rev 29:171-87. 2003....
- Population-based maximum tolerated dose of irinotecan and carboplatinCarolyn A Wild
University of California, Davis Cancer Center, Veterans Administration, Northern California Health Care System, Sacramento, California, USA
Oncology (Williston Park) 17:11-6. 2003..We recommend dose level 1 of irinotecan (200 mg/m2) and carboplatin (AUC 5) for chemotherapynaive patients, and dose level-1 of irinotecan (150 mg/m2) and carboplatin (AUC 5) for chemotherapy-treated patients in phase II trials...
- Endoscopic ultrasound-guided celiac plexus neurolysis for pancreatic cancer pain: a single-institution experience and review of the literatureQuy N H Tran
Department of Internal Medicine, University of California at Davis Medical Center, Sacramento 95817, USA
J Support Oncol 4:460-2, 464; discussion 463-4. 2006..We report our experience using EUS-guided CPN and review the available literature regarding this modality...
- Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733Celestia S Higano
Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
Cancer 112:2181-7. 2008..Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients...
- Diverse populations can use hospice services appropriatelyFrederick J Meyers
Am J Med 121:e1-2. 2008
- Simultaneous care: disease treatment and palliative care throughout illnessFrederick J Meyers
J Clin Oncol 21:1412-5. 2003
- Redesigning training for internal medicineJohn P Fitzgibbons
Ann Intern Med 145:865-6; author reply 866. 2006
- Confronting the brutal facts in health careMark C Henderson
Am J Med 118:1061-3. 2005
- Centers, Institutes, and the future of clinical departments: part ITod Ibrahim
Am J Med 115:337-41. 2003
- Centers, institutes, and the future of clinical departments: Part IIThomas B Crist
Am J Med 115:745-7. 2003
- Surgery for emphysemaFrederick J Meyers
N Engl J Med 346:860-2. 2002
- Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139Mark M Zalupski
Department of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Cancer 100:818-25. 2004....
- Simultaneous Care: Linking Palliation to Clinical TrialsFrederick Meyers; Fiscal Year: 2006..A comprehensive plan for the dissemination of the model and results to community and comprehensive cancer centers with follow-up to measure durable change completes this project. ..